Case Studies

Case Study: Leveraging Longitudinal Patient Data for Strategic Pharmaceutical Development

Background

A leading private healthcare provider in Eastern Europe, recognized for its extensive healthcare services, approached XpanMed to explore the commercial potential of their patient data accumulated over the past 20 years. This dataset was particularly valuable as it included longitudinal studies, tracking the same patients over time, and encompassed comprehensive electronic health records (EHRs) such as patient demographics, diagnostic codes, treatment histories, laboratory test results, and detailed outcome data. The data had been meticulously anonymized to adhere to GDPR and other pertinent data protection regulations.

Challenge

The primary challenge was to ascertain the utility and market value of this longitudinal data, which was extensive but varied in detail and format. The healthcare provider sought to understand how this data could be leveraged in pharmaceutical research, particularly for its potential to enhance drug development processes and outcomes.

Solution

XpanMed conducted an exhaustive analysis to evaluate the data characteristics and performed thorough due diligence on the quality of the anonymized dataset. This assessment included:

Data Validation: Ensuring accuracy and consistency across different periods.

Standardization Review: Confirming that the data formats and medical coding were current and aligned with international standards.

Gap Analysis: Identifying significant data gaps that might affect pharmaceutical research applications.

Subsequently, XpanMed identified a pharmaceutical company with a strong focus on developing treatments for chronic diseases, aligning with the longitudinal nature of the data. The partnership was structured to include:

Deal Structure: Flat Sum + Royalty

• Flat Sum Payment: An upfront payment acknowledging the immediate value of the data.

• Royalty Arrangement: A royalty agreement, granting the healthcare provider a percentage of the revenue from any new drugs developed using the data.

• Exclusive Access: Exclusive access to the dataset for a period of five years, enhancing the value of the agreement for the pharmaceutical company.

Outcome

The deal was valued at a multi-million dollar sum in flat payments, plus royalties tied to the commercial success of drugs developed using the data. This strategic agreement not only provided significant financial benefits to the healthcare provider but also ensured ongoing revenue potential linked to the success of pharmaceutical outcomes.

Impact

For the Healthcare Provider: The transaction significantly enhanced their financial resources, enabling further investment in medical technology and patient care. It also set a precedent for future data monetization efforts.

For the Pharmaceutical Company: The exclusive access to comprehensive, longitudinal health data accelerated their drug development timelines, particularly in the realm of chronic diseases, enhancing their ability to introduce effective new therapies to the market.

Conclusion

This case study exemplifies the significant value of historical patient data when appropriately leveraged through strategic partnerships. XpanMed's role in facilitating this partnership enabled both the healthcare provider and the pharmaceutical company to achieve substantial financial and medical research benefits, illustrating the transformative potential of well-curated data sets in advancing healthcare outcomes.